Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern-based recognition

被引：9

作者：

Das, Nupur ^{[1
]}

Dahiya, Meetu ^{[1
]}

Gupta, Ritu ^{[1
]}

Rai, Sandeep ^{[1
]}

Singh, Saroj ^{[1
]}

Prajapati, Vijay K. ^{[1
]}

Kumar, Lalit ^{[2
]}

Sharma, Atul ^{[2
]}

Sahoo, Ranjit K. ^{[2
]}

Gogia, Ajay ^{[2
]}

机构：

[1] All India Inst Med Sci AIIMS, Dept Lab Oncol, Dr BR Ambedkar IRCH, New Delhi 110029, India

[2] All India Inst Med Sci AIIMS, Dept Med Oncol, Dr BR Ambedkar IRCH, New Delhi, India

来源：

CYTOMETRY PART B-CLINICAL CYTOMETRY | 2022年 / 102卷 / 04期

关键词：

aberrant plasma cells; flow cytometry; normal plasma cells; plasma cell proliferative disorders; MINIMAL RESIDUAL DISEASE; MULTIPLE-MYELOMA; MRD DETECTION; CRITERIA; IDENTIFICATION;

D O I：

10.1002/cyto.b.22062

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Background The expression pattern of common antigens including cytoplasmic kappa/lambda ratio (cyKLR) was evaluated by flow cytometric immunophenotyping (FCMI) to explore their relevance in discriminating normal and aberrant plasma cells (NPC and APC, respectively) across spectrum of plasma cell proliferative disorders (PCPD). Methods In this prospective analysis, 791 samples from PCPD (treatment naive = 455; partially treated = 336) were evaluated for expression of CD38, CD138, CD45, CD19, CD56, CD27, CD81, CD117, Cy-kappa, and Cy-lambda using FCMI. Results Amongst the entire cohort, 20.7% (n = 164) samples displayed only APC, 21% (n = 165) only NPC and 58% (n = 462) showed coexistence of NPC and APC. Using pattern-based recognition (PBR) for three common patterns (CD19 vs. CD56; CD27 vs. CD56 and CD19 vs. CD27), APC was separable from NPC in 93% samples. In 6.5% samples, the gating markers contributed in APC-NPC differentiation and in the remaining 0.5% CD117 and CD81 proved useful. Clonality assessment was found to be crucial to label plasma cell compartment as completely normal or aberrant in 42% cases with either all NPC or all APC. Sixty one out of 462 cases (13%) revealed cyKLR within normal reference range and in these cases; abnormal cyKLR was demonstrable only after gating APC separately based on PBR. Conclusion Fair discrimination between NPC and APC is achievable in all PCPD samples using eight markers (Gating: CD38, CD138, CD45; PBR:CD19, CD56, CD27; clonality: Cy-kappa and Cy-lambda). Thus, combined assessment of clonality and immunophenotypic aberrancies is required for accurate, reliable and precise assessment of NPC and APC compartments in PCPD.

引用

页码：292 / 302

页数：11

共 22 条

[1] Consensus Guidelines on Plasma Cell Myeloma Minimal Residual Disease Analysis and Reporting [J].

Arroz, Maria ;

Came, Neil ;

Lin, Pei ;

Chen, Weina ;

Yuan, Constance ;

Lagoo, Anand ;

Monreal, Mariela ;

de Tute, Ruth ;

Vergilio, Jo-Anne ;

Rawstron, Andy C. ;

Paiva, Bruno .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (01) :31-39

[2]

Bataille R, 2006, HAEMATOLOGICA, V91, P1234

[3] Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow [J].

Boucher, Kelly ;

Parquet, Nancy ;

Widen, Raymond ;

Shain, Kenneth ;

Baz, Rachid ;

Alsina, Melissa ;

Koomen, John ;

Anasetti, Claudio ;

Dalton, William ;

Perez, Lia E. .

CLINICAL CANCER RESEARCH, 2012, 18 (22) :6155-6168

[4] Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates [J].

Cogbill, C. H. ;

Spears, M. D. ;

Vantuinen, P. ;

Harrington, A. M. ;

Olteanu, H. ;

Kroft, S. H. .

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, 37 (06) :797-808

[5]

Das N., 2021, RELEVANCE POLYCLONAL

[6] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[7] Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma [J].

Flores-Montero, J. ;

Sanoja-Flores, L. ;

Paiva, B. ;

Puig, N. ;

Garcia-Sanchez, O. ;

Boettcher, S. ;

van der Velden, V. H. J. ;

Perez-Moran, J-J ;

Vidriales, M-B ;

Garcia-Sanz, R. ;

Jimenez, C. ;

Gonzalez, M. ;

Martinez-Lopez, J. ;

Corral-Mateos, A. ;

Grigore, G-E ;

Fluxa, R. ;

Pontes, R. ;

Caetano, J. ;

Sedek, L. ;

del Canizo, M-C ;

Blade, J. ;

Lahuerta, J-J ;

Aguilar, C. ;

Barez, A. ;

Garcia-Mateo, A. ;

Labrador, J. ;

Leoz, P. ;

Aguilera-Sanz, C. ;

San-Miguel, J. ;

Mateos, M-V ;

Durie, B. ;

van Dongen, J. J. M. ;

Orfao, A. .

LEUKEMIA, 2017, 31 (10) :2094-2103

[8] Immunophenotype of Normal vs. Myeloma Plasma Cells: Toward Antibody Panel Specifications for MRD Detection in Multiple Myeloma [J].

Flores-Montero, Juan ;

de Tute, Ruth ;

Paiva, Bruno ;

Juan Perez, Jose ;

Boettcher, Sebastian ;

Wind, Henk ;

Sanoja, Luzalba ;

Puig, Noemi ;

Lecrevisse, Quentin ;

Belen Vidriales, Maria ;

van Dongen, Jacques J. M. ;

Orfao, Alberto .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (01) :61-72

[9] Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma [J].

Gupta, Ritu ;

Bhaskar, Archana ;

Kumar, Lalit ;

Sharma, Atul ;

Jain, Paresh .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (05) :728-732

[10] EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols [J].

Kalina, T. ;

Flores-Montero, J. ;

van der Velden, V. H. J. ;

Martin-Ayuso, M. ;

Boettcher, S. ;

Ritgen, M. ;

Almeida, J. ;

Lhermitte, L. ;

Asnafi, V. ;

Mendonca, A. ;

de Tute, R. ;

Cullen, M. ;

Sedek, L. ;

Vidriales, M. B. ;

Perez, J. J. ;

te Marvelde, J. G. ;

Mejstrikova, E. ;

Hrusak, O. ;

Szczepanski, T. ;

van Dongen, J. J. M. ;

Orfao, A. .

LEUKEMIA, 2012, 26 (09) :1986-2010

← 1 2 3 →